|Bid||1,419.80 x 0|
|Ask||1,420.20 x 0|
|Day's range||1,409.20 - 1,420.80|
|52-week range||1,190.80 - 1,528.80|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||13.63|
|Earnings date||27 Oct 2021|
|Forward dividend & yield||0.80 (5.57%)|
|Ex-dividend date||20 May 2021|
|1y target est||N/A|
What happened Shares of the genetic-testing company 23andMe (NASDAQ: ME) gained another 16% through Thursday's close this week, according to data from S&P Global Market Intelligence. The biotech's stock is now up by more than 34% over the past two weeks.
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.